Could Serum Sclerostin Help in Early Assessment and Treatment of Chronic Kidney Disease – Mineral and Bone Disorder?

Open access

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Hill NR Fatoba ST Oke JL et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PloS One 2016; 11(7): e0158765.

  • 2. Hruska KA Sugatani T Agapova O et al. The chronic kidney disease – mineral and bone disorder (CKD-MBD): Advances in pathophysiology. Bone 2017; 100: 80–86.

  • 3. Winkler DG Sutherland MK Geoghegan JC et al. Osteocyte control of bone formation via sclerostin a novel BMP antagonist. EMBO J 2003; 22: 6267–6276.

  • 4. Figurek A Spasovski G. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder? Int Urol Nephrol 2018; 50(10): 1863–1870.

  • 5. Cejka D Marculescu R Kozakowski N et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 2014; 99: 248–255.

  • 6. Sabbagh Y Graciolli FG O’Brien S et al. Repression of osteocyte Wnt/-catenin signaling is an early event in the progression of renal osteodystrophy. J. Bone. Miner. Res. 2012; 27: 1757–1772

  • 7. Bielesz BO Hempfing T Kieweg H et al. Sclerostin declines during hemodialysis and appears in Dialysate. Blood Purif 2014; 38: 30–36.

  • 8. Yamada S Tsuruya K Tokumoto M et al. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis. Nephrology (Carlton) 2015; 20: 639–645.

  • 9. Desjardins L Liabeuf S Oliveira R.B et al. Uremic toxicity and sclerostin in chronic kidney disease patients. J Clin Endocrinol Metab 2014; 99: E1854-61.

  • 10. Satoa M Hanafusab N Kawaguchia H et al. A Prospective Cohort Study Showing No Association Between Serum Sclerostin Level and Mortality in Maintenance Hemodialysis Patients. Kidney Blood Press Res 2018; 43: 1023–1033

  • 11. Carvalho Goncalves FL Elias RM dos Reis L.M et al. Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrology 2014; 15: 190.

  • 12. Drechsler C Evenepoel P Vervloet MG et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2015; 30: 288–293.

  • 13. Nowak A Artunc F Serra AL et al. Sclerostin quo vadis ? – Is this a useful long-term mortality parameter in prevalent hemodialysis patients? Kidney Blood Press Res 2015; 40: 266–276.

  • 14. Sooling ASK Harslof T Langdahl B. The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis 2018; 10(5-6): 105–115.

  • 15. Brandenburg VM Verhulst A Babler A et al. Sclerostin in chronic kidney disease – mineral and bone disorder think before you block it! Nephrol Dial Transplant 2018 May 24. doi: 10.1093/ndt/gfy129.

  • 16. Xue-Li Du Wen-Bo Li and Bo-Jie Hu. (2018) Application of artificial intelligence in ophthalmology. Int J Ophthalmol 11(9): 1555–1561.

Journal information
Impact Factor

CiteScore 2017: 0.45

SCImago Journal Rank (SJR) 2018: 0.177

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 104 104 26
PDF Downloads 69 69 11